Stock Information

Markets
TSX20590.98+19.68
TSXV847.21+8.80
DOW34297.73-66.77
S&P 5004356.45-53.68
NASD13539.29-315.83
ASX6961.60-177.90
Commodities
Gold1846.90-2.64
Silver23.92+0.03
Copper4.53+0.08
Palladium2244.50+57.50
Platinum1046.00+17.00
Oil86.16+0.56
Heating Oil2.65+0.02
Natural Gas4.25+0.20
Currencies
BTCUSD37832.66+1022.94
USDCAD1.2570-0.0048
USDEUR0.8864+0.0018
USDGBP0.7400-0.0002
USDAUD1.3936-0.0034
USDJPY114.16+0.27

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION), covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregation in Parkinson's disease (PD).

Keep reading... Show less

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

  • iX Biopharma will receive an initial US$9 million upfront payment
  • Eligible for up to US$239 million in development and sales milestone payments
  • Double digit royalties on future product sales of any licensed product

IX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Keep reading... Show less
×